Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
Cassie PanQian Vicky WuJenna VoutsinasJeffrey J HoultonBrittany BarberNeal FutranGeorge E LaramoreJay J LiaoUpendra ParvathaneniRenato G MartinsJonathan R FrommCristina P RodriguezPublished in: Head & neck (2022)
In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.